STAT

A writer shared her story about getting frightening genetic results online. The response was surprising

A writer shared her story about getting frightening genetic results online. The response was surprising.

This is a lightly edited transcript from a recent episode of STAT’s biotech podcast, “The Readout LOUD.” Like it? Consider subscribing to hear every episode.

Over the past decade, more than 25 million people have ordered at-home DNA testing kits from companies like 23andMe and Ancestry.com. You spit in a tube, send it away, and get notified by email when your results are ready. Initially aimed at providing information about ancestry, some companies now test for certain genetic mutations that are strongly correlated with the risk of developing cancer, Alzheimer’s disease, or other serious conditions.

Dorothy Pomerantz is one of those 25 million people. Last year, almost on a lark, she bought a 23andMe test and sent her spit to Silicon Valley. But what she learned went far beyond the for STAT’s First Opinion, and spoke with STAT about the reaction to it.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks